Lipopeptides

The Lundquist Institute Out-Licenses Development of a Synthetic Lung Surfactant Formulation

Retrieved on: 
Monday, March 8, 2021

This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated.

Key Points: 
  • This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated.
  • "Naturally-occurring lung surfactant is a lipid-protein mixture that prevents lung collapse through surface tension reduction," said Frans Walther, MD, the lead Lundquist Investigator.
  • "Lack of lung surfactant leads to respiratory distress syndrome in premature infants and can be treated with animal-derived surfactant administration into the windpipe.
  • Our research demonstrated that inhalation of a dry powder synthetic lung surfactant formulation with an advanced surfactant protein analog can improve breathing and lung function in surfactant-deficient animals.

Dr. Reddy’s Q3 & 9M FY21 Financial Results

Retrieved on: 
Friday, January 29, 2021

This included Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and Succinylcholine Chloride Injection in the US along with Daptomycin Injection in Canada.

Key Points: 
  • This included Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and Succinylcholine Chloride Injection in the US along with Daptomycin Injection in Canada.
  • As of 31st December 2020, cumulatively 89 generic filings are pending for approval with the USFDA (87 ANDAs and 2 NDAs under 505(b)(2) route).
  • Of the 89 ANDAs, 48 are Para IVs and we believe 24 have First to File status.
  • As % to revenues these are: Q3 FY21: 8.3% | Q2 FY 21: 8.9% | Q3 FY20: 9.0%.

Cubicin: 2019 Drug Insight Report with Sales Forecasting to 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 12, 2019

The "Cubicin - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cubicin - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Cubicin Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of Cubicin, covering the historical global sales and also provides the Cubicin sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Cubicin and emerging therapies in this space.

Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Retrieved on: 
Wednesday, May 15, 2019

The Cubicin for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.

Key Points: 
  • The Cubicin for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.
  • Dr. Reddys Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.
  • Cubicin is a trademark of Merck Sharp & Dohme Corp.
    About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.